You just read:

Allergan Receives Refusal to File Letter from FDA for Vraylar® (cariprazine) Supplemental New Drug Application (sNDA) for the Treatment of Negative Symptoms in Schizophrenia

News provided by

Allergan plc

Sep 22, 2017, 16:49 ET